Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A pharmacist's touch: could structured medication reviews boost HIV treatment success?

NCT ID NCT07750834

Disease control Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This trial tests whether a structured, pharmacist-led medication management program can help HIV patients at high risk of drug-related problems take their medications more consistently. Participants are randomly assigned to usual care, a basic program, or an enhanced program with extra support like pill organizers and home visits. The study tracks adherence, viral load, and quality of life over 24 months to see if the extra support makes a meaningful difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacist-led Medication Therapy Management (MTM) program
What this could lead to
If effective, this program could become a standard approach to help HIV patients stick to their medications, potentially improving viral suppression and quality of life in resource-limited settings.
What could go wrong
The trial is early and the outcome depends on patient engagement and healthcare infrastructure. Results may not generalize beyond this specific setting, and the added pharmacist time may not prove cost-effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,149 people

The number who actually took part.

Started

Jan 2021

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age: ≥18 years at the time of enrollment. * HIV Status: Laboratory-confirmed HIV infection. * ART Duration: Receiving antiretroviral therapy (ART) for at least 3 months prior to enrollment. --Language and Consent: Able to communicate in Arabic or English and willing and able to provide written informed consent. * High-Risk Status: Meeting at least 2 of the following high-risk criteria: * Receiving ≥8 chronic medications, including ART and medications for comorbidities. * Having ≥3 chronic comorbidities (e.g., diabetes mellitus, hypertension, hepatitis, or tuberculosis). * Documented or self-reported adverse drug event within the previous 12 months. * Viral load \>200 copies/mL during the previous 6 months. --Self-reported medication adherence \<95% or repeated missed clinic appointments. * Attendance at the participating HIV clinic on at least 2 occasions during the assessment period. Exclusion Criteria: * Age \<18 years. * Pregnancy. * Significant cognitive impairment preventing informed consent or study participation. * Terminal illness with expected life expectancy \<12 months. * Concurrent participation in another pharmacological intervention study. * Previous participation in a formal Medication Therapy Management (MTM) program within the past year. * Planned relocation away from Khartoum State during the follow-up period. * Inability to provide informed consent for any reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS Drug-Related Side Effects and Adverse Reactions HIV infectious disease Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections

Contacts and locations

Locations

  • Omdurman teaching Hospital

    Khartoum, Omdurman, 1111, Sudan

More trials for these conditions

Other studies related to the condition(s) this trial covers.